The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population

Current Oncology

Volumn 20, Issue 4, 2013, Pages 212-219

  Nichols, A C ^a,b,c   Palma, D A ^a,b,c   Dhaliwal, S S ^a   Tan, S ^a   Theuer, J ^a   Chow, W ^a   Rajakumar, C ^a   Um, S ^a   Mundi, N ^a   Berk, S ^a   Zhou, R ^a   Basmaji, J ^a   Rizzo, G ^a   Franklin, J H ^a,b   Fung, K ^a,b   Kwan, K ^a   Wehrli, B ^a   Salvadori, M I ^a   Winquist, E ^a,b   Ernst, S ^a,b   Kuruvilla, S ^a,b   Read, N ^a,b   Venkatesan, V ^a,b   Todorovic, B ^a,b   Hammond, J A ^a,b   Koropatnick, J ^a,b,c   Mymryk, J S ^a,b,c   Yoo, J ^a,b   Barrett, J W ^a,b,c   more..

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Lawson Health Research Institute ^*

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Epidemiology; HNSCC; Human papillomavirus; Oropharyngeal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; VIRUS DNA;

ADULT; ARTICLE; CANADA; CANCER INCIDENCE; CANCER STAGING; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; EPIDEMIC; FACTUAL DATABASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TONSIL CANCER; TREATMENT OUTCOME; TREND STUDY; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS;

EID: 84881242764     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1375     Document Type: Article

References (19)

1. Reid JL, Hammond D, Burkhalter R, Ahmed R, Tobacco Use in Canada: Patterns and Trends, 2012 Edition. Waterloo, ON: Propel Centre for Population Health Impact, University of Waterloo; 2012.
2. Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, Rosin M. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (hpv)-related and hpv-unrelated sites in a multicultural population: the British Columbia experience. Cancer 2010;116:2635-2644.
3. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-4301.
4. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (hpv) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362-366.
5. Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JR, Brisson M. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009;36:380-386.
6. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
7. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of hpv in Ontario Women (show) Group. CMAJ 2000;163:503-508.
8. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
9. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
10. Nichols AC, Faquin WC, Westra WH, et al., hpv-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2009;140:228-234.
11. Nichols AC, Yoo J, Hammond JA, et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (orator)-study protocol for a randomized phase ii trial. BMC Cancer 2013;13:133.
12. Johnson-Obaseki S, McDonald JT, Corsten M, Rourke R. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg 2012;147:74-78.
13. Nichols AC, Dhaliwal SS, Palma DA, et al. Does hpv type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg 2013;42:9.
14. Nichols AC, Finkelstein DM, Faquin WC, et al. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res 2010;16:2138-46.
15. Jordan RC, Lingen MW, Perez-Ordonez B, et al. Validation of methods for oropharyngeal cancer hpv status determination in US cooperative group trials. Am J Surg Pathol 2012;36:945-54.
16. Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996;88:1361-8.
17. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto, ON: Canadian Cancer Society; 2006.
18. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an rtog analysis. J Clin Oncol 2008;26:3582-9.
19. O'Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013;31:543-50.